Compare INSP & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSP | BLCO |
|---|---|---|
| Founded | 2007 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Ophthalmic Goods |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 6.0B |
| IPO Year | 2018 | 2022 |
| Metric | INSP | BLCO |
|---|---|---|
| Price | $130.44 | $16.99 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 16 | 14 |
| Target Price | ★ $132.27 | $17.31 |
| AVG Volume (30 Days) | ★ 1.7M | 399.7K |
| Earning Date | 11-03-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.77 | N/A |
| EPS | ★ 1.48 | N/A |
| Revenue | $882,622,000.00 | ★ $4,976,000,000.00 |
| Revenue This Year | $14.97 | $8.08 |
| Revenue Next Year | $11.81 | $5.77 |
| P/E Ratio | $88.30 | ★ N/A |
| Revenue Growth | ★ 16.81 | 6.23 |
| 52 Week Low | $70.77 | $10.45 |
| 52 Week High | $216.01 | $18.99 |
| Indicator | INSP | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 63.19 | 60.98 |
| Support Level | $132.39 | $16.39 |
| Resistance Level | $147.03 | $17.41 |
| Average True Range (ATR) | 8.60 | 0.46 |
| MACD | 0.20 | 0.06 |
| Stochastic Oscillator | 62.23 | 72.71 |
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.